Therma Bright Inc (OTCMKTS:TBRIF) (TSXV:THRM) Expects Canadian Approval for AcuVid(TM) COVID-19 Rapid Antigen Saliva Test

The medical device sector has come under a lot of focus in recent times and if you are currently looking into such stocks then you could consider taking a look at the medical device technology company Therma Bright Inc (OTCMKTS:TBRIF) (TSXV: THRM).

As a matter of fact, the company was in fact in the news on Tuesday after it made a key announcement and it may be a good move to take a closer look at it. The company announced yesterday that it was going to submit an application for its AcuVid™ COVID-19 Rapid Antigen Saliva Test to Health Canada for the purpose of detecting the COVID 19 virus in human saliva. It goes without saying that the announcement was a significant one and one that could bring considerable focus to the Therma Bright stock.

The application that the company is going to send to Health Canada had been sent under the provisions of the guidelines of the Emergency Use Authorisation that are in place at the United States Food and Drug Administration. Such an application had already been sent in by the company to the FDA back on March 29 this year. The application that is going to be sent to Health Canada is going to be guided by the Interim Order that had been issued by the agency.

The application is going to be fairly similar to the one that had been sent to the FDA. In addition to that, it would also provide the data from the test performances that had been conducted in clinical studies in Brazil and United States.

In addition to that, the product manufacturing data had also been sent to the FDA and the same is expected to be sent to Health Canada as well. It may be a good idea to keep an eye on the Therma Bright stock in the coming days.